ClinicalTrials.gg

Program

atirmociclib

Also written as “PF-07220060 + PF-07104091 combination dose escalation”, “PF-07220060” and “Atirmociclib”.

In Pfizer's pipeline, CDK4 inhibitor. Its studies are mostly in Breast Neoplasms · Liposarcoma · Hepatic Insufficiency, led by 4 companies.

Furthest: phase 3, since Dec 11, 202417 company-led studies, 10 open or runningNext primary completion: Feb 26, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer147 open or runningphase 3since Dec 11, 2024Sep 15, 2020Feb 26, 2027phase 2 · NCT05262400
AstraZeneca11 open or runningphase 2since Feb 16, 2026Feb 16, 2026Dec 28, 2027phase 2 · NCT07427394
Hoffmann-La Roche11 open or runningphase 2since Jan 30, 2018Jan 30, 2018Sep 30, 2030phase 2 · NCT03424005
Olema Pharmaceuticals11 open or runningphase 1since Aug 16, 2022Aug 16, 2022Dec 31, 2027phase 1 · NCT05508906
  • Named in Pfizer’s own pipeline as atirmociclib PF-07220060, phase 3, as of Nov 3, 2026 (source).

Also a collaborator on its studies: Gilead Sciences, arvinas-estrogen-receptor-inc and Novartis.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Jan 30, 2018.

  1. Aug 16, 2022Olema Pharmaceuticals's first study: phase 1 study in Breast NeoplasmsNew to Olema PharmaceuticalsOlema Pharmaceuticals · NCT05508906 · 190 enrolled · United States, Australia
  2. Jun 20, 2023Phase 1 study in Healthy ParticipantsPfizer · NCT05923411 · 113 enrolled · United States
  3. Oct 24, 2023Phase 2 study in Breast NeoplasmsPfizer · NCT06105632 · 333 enrolled · United States, Argentina, Australia and more
  4. Dec 13, 2023Phase 2 study in Breast NeoplasmsPfizer · NCT06206837 · 71 enrolled · United States, Belgium, Canada and more
  5. Jan 17, 2024Phase 1 study in Healthy ParticipantsPfizer · NCT06267963 · 12 enrolled · Netherlands
  6. Jun 13, 2024Phase 2 study in Breast NeoplasmsPfizer · NCT06465368 · 121 enrolled · United States, Australia, Belgium and more
  7. Dec 11, 2024Phase 3 study in Breast NeoplasmsPfizer · NCT06760637 · 1,035 enrolled · United States, Argentina, Australia and more
  8. Mar 20, 2025Phase 1 study in Healthy AdultsPfizer · NCT06897683 · 14 enrolled · United States
  9. Aug 12, 20252 phase 1 studiesPfizer · NCT07130097, NCT07160738
  10. Oct 8, 2025Phase 1 study in Healthy VolunteerPfizer · NCT07215078 · 72 enrolled · United States
  11. Feb 16, 2026AstraZeneca's first study: phase 2 study in Advanced Breast CancerNew to AstraZenecaAstraZeneca · NCT07427394 · 24 planned · United States, United Kingdom
  12. Jun 24, 2026Phase 1 study in Hepatic InsufficiencyPfizer · NCT07677358 · 28 planned · United States
  13. Oct 16, 2026Phase 3 study in Breast NeoplasmsPfizer · NCT07890597 · 3,800 planned
  14. Oct 21, 2026Primary completion moved from 2026-09-23 to 2029-10-07Date moved laterphase 2 · +36 months · NCT04557449

Ahead

  1. Feb 26, 2027Primary completion: phase 2 study in Breast NeoplasmsPfizer · NCT05262400
  2. Aug 14, 2027Primary completion: phase 1 study in Hepatic InsufficiencyPfizer · NCT07677358
  3. Dec 28, 2027Primary completion: phase 2 study in Advanced Breast CancerAstraZeneca · NCT07427394
  4. Dec 31, 2027Primary completion: phase 1 study in Breast NeoplasmsOlema Pharmaceuticals · NCT05508906

TargetBeta

“CDK4 inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable inhibitor of cyclin-dependent kinase 4 (CDK4), with potential antineoplastic activity. Upon administration, atirmociclib selectively inhibits CDK4, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase tran…”NCIt, read by Claude
“An orally bioavailable inhibitor of cyclin-dependent kinase 4 (CDK4), ”NCIt, by rule

Other programs on CDK4

ProgramCompanyFurthest phaseStudies
abemaciclibruleEli Lillyphase 449
palbociclibrulePfizerphase 436
trilaciclibrulePharmacosmosphase 414
culmerciclibSino Biopharmaceuticalphase 311
HRS-6209Jiangsu HengRui Medicinephase 37
CDK4 Inhibitor BGB-43395ruleBeOne Medicinesphase 34
narazaciclibrulehangzhou-hanx-biopharmaceuticals-ltdphase 24
vustanaciclibregor-pharmaceuticals-incphase 23
CG-7321rulechengdu-cynogen-bio-pharmaceutical-tech-co-ltdphase 11
nkt5097 cdk2rulenikang-therapeutics-incphase 11
TSL2109ruleChina Resources Pharmaceutical Groupphase 11

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07890597Breast Neoplasms3Not yet recruitingPfizerApr 13, 20323,800
NCT07677358Hepatic Insufficiency · United States1RecruitingPfizerAug 14, 202728
NCT07427394Advanced Breast Cancer · United States, United Kingdom2RecruitingAstraZenecaDec 28, 202724
NCT07215078Healthy Volunteer · United States1CompletedPfizerJul 21, 202672
NCT07160738Breast Neoplasms · United States1CompletedPfizerNov 24, 202525
NCT07130097Healthy Participant · United States1CompletedPfizerOct 26, 202535
NCT06897683Healthy Adults · United States1CompletedPfizerMay 11, 202514
NCT06760637Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingPfizerJan 2, 20291,035
NCT06465368Breast Neoplasms · United States, Australia, Belgium and more2CompletedPfizerJul 10, 2025121
NCT06267963Healthy Participants · Netherlands1CompletedPfizerApr 12, 202412
NCT06206837Breast Neoplasms · United States, Belgium, Canada and more2Active, not recruitingPfizerSep 5, 202571
NCT06105632Breast Neoplasms · United States, Argentina, Australia and more2Active, not recruitingPfizerJan 12, 2026333
NCT05923411Healthy Participants · United States1CompletedPfizerJun 23, 2024113
NCT05508906Breast Neoplasms · United States, Australia1Active, not recruitingOlema PharmaceuticalsDec 31, 2027190
NCT05262400Breast Neoplasms · United States, Argentina, Brazil and more2Active, not recruitingPfizerFeb 26, 2027235
NCT04557449Liposarcoma · United States, Argentina, China and more2RecruitingPfizerOct 7, 2029430
NCT03424005Breast Neoplasms · United States, Australia, France and more2RecruitingHoffmann-La RocheSep 30, 20301,132

How it is read

Names in the registry

  • “PF-07220060 + PF-07104091 combination dose escalation”, 8 entries
  • “PF-07220060”, 7 entries
  • “Atirmociclib”, 5 entries
  • “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, 2 entries
  • “Single dose of PF-07220060 as first Tablet Formulation”, 2 entries

Codes read as this program: PF07220060.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.